Related references
Note: Only part of the references are listed.Cytokine-enhanced cytolytic activity of exosomes from NK Cells
Yutaka Enomoto et al.
CANCER GENE THERAPY (2022)
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Mengling Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
The therapeutic potential of immune cell-derived exosomes as an alternative to adoptive cell transfer
Yeonsun Hong et al.
BMB REPORTS (2022)
Extracellular vesicles: mediators of intercellular communication in tissue injury and disease
Greg Berumen Sanchez et al.
CELL COMMUNICATION AND SIGNALING (2021)
Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4
Vijay G. Bhoj et al.
MOLECULAR THERAPY-ONCOLYTICS (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Human fibroblast-derived extracellular vesicles promote hair growth in cultured human hair follicles
Ramya Lakshmi Rajendran et al.
FEBS LETTERS (2021)
Genetic engineering of T cells for immunotherapy
Gavin I. Ellis et al.
NATURE REVIEWS GENETICS (2021)
CD19 Chimeric Antigen Receptor-Exosome Targets CD19 Positive B-lineage Acute Lymphocytic Leukemia and Induces Cytotoxicity
Shabirul Haque et al.
CANCERS (2021)
Identification of Angiogenic Cargo in Extracellular Vesicles Secreted from Human Adipose Tissue-Derived Stem Cells and Induction of Angiogenesis In Vitro and In Vivo
Prakash Gangadaran et al.
PHARMACEUTICS (2021)
Extracellular Vesicles Derived from Chimeric Antigen Receptor-T Cells: A Potential Therapy for Cancer
Anat Aharon et al.
HUMAN GENE THERAPY (2021)
Intercellular communication through extracellular vesicles in cancer and evolutionary biology
Scott E. Bonner et al.
PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY (2021)
Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma
Dongrui Wang et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy
Filippo Galli et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)
Extracellular vesicles derived from different sources of mesenchymal stem cells: therapeutic effects and translational potential
Jiaxin Cai et al.
CELL AND BIOSCIENCE (2020)
Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy
Yuki Kagoya et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Macrophage-Derived Extracellular Vesicle Promotes Hair Growth
Ramya Lakshmi Rajendran et al.
CELLS (2020)
Extracellular Vesicle- and Extracellular Vesicle Mimetics-Based Drug Delivery Systems: New Perspectives, Challenges, and Clinical Developments
Prakash Gangadaran et al.
PHARMACEUTICS (2020)
Extracellular vesicles derived from macrophage promote angiogenesis In vitro and accelerate new vasculature formation In vivo
Prakash Gangadaran et al.
EXPERIMENTAL CELL RESEARCH (2020)
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Rossana Franzin et al.
FRONTIERS IN IMMUNOLOGY (2020)
The Landscape of CAR-T Cell Clinical Trials against Solid Tumors-A Comprehensive Overview
Niels Schaft
CANCERS (2020)
B7-H3 Chimeric Antigen Receptor Redirected T Cells Target Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma
Zhenguo Zi et al.
CANCERS (2020)
Exosome-based immunotherapy: a promising approach for cancer treatment
Zhijie Xu et al.
MOLECULAR CANCER (2020)
Immunophenotypic and molecular analysis of a B cell lymphoma with discordant light chain expression at different anatomic sites
Belinda K. Galeano et al.
JOURNAL OF HEMATOPATHOLOGY (2020)
Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies
Yun Liu et al.
THERANOSTICS (2020)
Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells
Hongwei Du et al.
CANCER CELL (2019)
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma
Adam D. Cohen et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies
Lynsey M. Whilding et al.
CANCERS (2019)
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
Bryan D. Choi et al.
NATURE BIOTECHNOLOGY (2019)
CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
Ru Zhou et al.
FRONTIERS IN IMMUNOLOGY (2019)
The efficacy of third generation anti-HER2 chimeric antigen receptor T cells in combination with PD1 blockade against malignant glioblastoma cells
Luxi Shen et al.
ONCOLOGY REPORTS (2019)
B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres
Dean Nehama et al.
EBIOMEDICINE (2019)
Cancer and the Immune System: The History and Background of Immunotherapy
Maura Abbott et al.
SEMINARS IN ONCOLOGY NURSING (2019)
CXCR1-or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors
Linchun Jin et al.
NATURE COMMUNICATIONS (2019)
CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
Wenyan Fu et al.
NATURE COMMUNICATIONS (2019)
CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy
Michael C. Burger et al.
FRONTIERS IN IMMUNOLOGY (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Chimeric Antigen Receptor T-cell (CAR T) Therapy for Hematologic and Solid Malignancies: Efficacy and Safety-A Systematic Review with Meta-Analysis
Wen-Liang Yu et al.
CANCERS (2019)
Chimeric antigen receptor T-cell therapies for lymphoma
Jennifer N. Brudno et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma
Kevin Bielamowicz et al.
NEURO-ONCOLOGY (2018)
Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions
Catherine E. Handy et al.
FUTURE ONCOLOGY (2018)
Role of T cell-derived exosomes in immunoregulation
Jian Lu et al.
IMMUNOLOGIC RESEARCH (2018)
Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T
Dok Hyun Yoon et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells
Yali Han et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy
Serena Pellegatta et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial
Yao Wang et al.
ONCOIMMUNOLOGY (2018)
Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma
Zhongzhen Yi et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2018)
Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells
Reza Elahi et al.
FRONTIERS IN IMMUNOLOGY (2018)
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
Michael M. Boyiadzis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity
Dongrui Wang et al.
JCI INSIGHT (2018)
Targeting and suppression of HER3-positive breast cancer by T lymphocytes expressing a heregulin chimeric antigen receptor
Bai-Le Zuo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
Chun-Meng Wang et al.
CLINICAL CANCER RESEARCH (2017)
Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen
S. Rafiq et al.
LEUKEMIA (2017)
GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)-AN INTERIM ANALYSIS
S.J. Schuster et al.
HEMATOLOGICAL ONCOLOGY (2017)
Human CD3+T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells
Rusheni Munisvaradass et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.
Frank (Xiaohu) Fan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Fully human CD19-specific chimeric antigen receptors for T-cell therapy
D. Sommermeyer et al.
LEUKEMIA (2017)
Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains
Leah Alabanza et al.
MOLECULAR THERAPY (2017)
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Frederick L. Locke et al.
MOLECULAR THERAPY (2017)
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Donald M. O'Rourke et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma A Phase 1 Dose-Escalation Trial
Nabil Ahmed et al.
JAMA ONCOLOGY (2017)
CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors
Irene M. Min et al.
CLINICAL CANCER RESEARCH (2017)
Chimeric antigen receptor T-cell therapies for multiple myeloma
Lekha Mikkilineni et al.
BLOOD (2017)
First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results.
Jesus G. Berdeja et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Syed Abbas Ali et al.
BLOOD (2016)
Toxicities of chimeric antigen receptor T cells: recognition and management
Jennifer N. Brudno et al.
BLOOD (2016)
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
Robert Chen et al.
BLOOD (2016)
Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies
Marianna Sabatino et al.
BLOOD (2016)
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma
Marco Ruella et al.
CLINICAL CANCER RESEARCH (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
Partow Kebriaei et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape (Publication with Expression of Concern. See vol. 129, pg. 3464, 2019)
Meenakshi Hegde et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
Marco Ruella et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells
Cameron J. Turtle et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management
Paola Savoia et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
CAR T Cell Therapy: A Game Changer in Cancer Treatment
Hilde Almasbak et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2016)
Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report
Wen-ying Zhang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2016)
T Cells Expressing a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor Induce Remissions of Advanced Lymphoma in a First-in-Humans Clinical Trial
Jennifer N. Brudno et al.
BLOOD (2016)
The development of potential antibody-based therapies for myeloma
Daniel W. Sherbenou et al.
BLOOD REVIEWS (2015)
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
Zeguo Zhao et al.
CANCER CELL (2015)
T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia
Armen Mardiros et al.
CURRENT OPINION IN HEMATOLOGY (2015)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Alfred L. Garfall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis
Tengfei Zhang et al.
ONCOTARGET (2015)
Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies
Saar Gill et al.
IMMUNOLOGICAL REVIEWS (2015)
Molecular and cellular insights into T cell exhaustion
E. John Wherry et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Chimeric T Cells for Therapy of CD30+Hodgkin and Non-Hodgkin Lymphomas
Carlos A. Ramos et al.
BLOOD (2015)
A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy
Brian Philip et al.
BLOOD (2014)
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
Marcela V. Maus et al.
BLOOD (2014)
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
Saar Gill et al.
BLOOD (2014)
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
Shannon L. Maude et al.
CANCER JOURNAL (2014)
CD3ζ based chimeric antigen receptors mediate T cell activation via cis-and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy
J. S. Bridgeman et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2014)
Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells
Yao Wang et al.
CLINICAL IMMUNOLOGY (2014)
Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo
I. Pizzitola et al.
LEUKEMIA (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Gregory L. Beatty et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Waleed Haso et al.
BLOOD (2013)
T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia
Armen Mardiros et al.
BLOOD (2013)
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
Gerald P. Linette et al.
BLOOD (2013)
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
James N. Kochenderfer et al.
BLOOD (2013)
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
David T. Teachey et al.
BLOOD (2013)
A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells
Yu-Hsiang Chang et al.
CANCER RESEARCH (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia
Eric Tran et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma
Meenakshi Hegde et al.
MOLECULAR THERAPY (2013)
Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia
David S. Ritchie et al.
MOLECULAR THERAPY (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
Marcela V. Maus et al.
CANCER IMMUNOLOGY RESEARCH (2013)
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
James N. Kochenderfer et al.
BLOOD (2012)
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
Brian G. Till et al.
BLOOD (2012)
Mesothelin, a novel immunotherapy target for triple negative breast cancer
Julia Tchou et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Infusing CD19-Directed T Cells to Augment Disease Control in Patients Undergoing Autologous Hematopoietic Stem-Cell Transplantation for Advanced B-Lymphoid Malignancies
Partow Kebriaei et al.
HUMAN GENE THERAPY (2012)
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
John Scholler et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells
Cor H. J. Lamers et al.
BLOOD (2011)
In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor
Greta Maria Paola Giordano Attianese et al.
BLOOD (2011)
A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells
Xiuli Wang et al.
BLOOD (2011)
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Renier J. Brentjens et al.
BLOOD (2011)
The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor
Z. Jin et al.
GENE THERAPY (2011)
Treatment of Advanced Leukemia in Mice with mRNA Engineered T Cells
David M. Barrett et al.
HUMAN GENE THERAPY (2011)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Antonio Di Stasi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Michael Kalos et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CDI9-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
Michael C. Jensen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor
Michael Hudecek et al.
BLOOD (2010)
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer et al.
BLOOD (2010)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b
John A. Craddock et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell-mediated Tumor Eradication
Xiao-Song Zhong et al.
MOLECULAR THERAPY (2010)
Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial
Renier Brentjens et al.
MOLECULAR THERAPY (2010)
A Transposon and Transposase System for Human Application
Perry B. Hackett et al.
MOLECULAR THERAPY (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
Antonio Di Stasi et al.
BLOOD (2009)
Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy
Marieke Griffioen et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
Karl S. Peggs et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
Michael C. Milone et al.
MOLECULAR THERAPY (2009)
Graft-versus-host disease after donor leukocyte infusions: presentation and management
Noelle V. Frey et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2008)
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Brian G. Till et al.
BLOOD (2008)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
Epstein!Barr virus-specific cytotoxic T lymphocytes expressing the anti-CD30ξ artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease
Barbara Savoldo et al.
BLOOD (2007)
PD-1 and PD-1 ligands: from discovery to clinical application
Taku Okazaki et al.
INTERNATIONAL IMMUNOLOGY (2007)
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
Michael H. Kershaw et al.
CLINICAL CANCER RESEARCH (2006)
Hurdles to lymphocyte trafficking in the tumor microenvironment: Implications for effective immunotherapy
Daniel T. Fisher et al.
IMMUNOLOGICAL INVESTIGATIONS (2006)
Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in Cell Factories
M Przybylowski et al.
GENE THERAPY (2006)
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells
L Gattinoni et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival
AJ Novak et al.
BLOOD (2004)
MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213Bi-C595 radioimmunoconjugate
CF Qu et al.
BRITISH JOURNAL OF CANCER (2004)
Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades
J Jacob et al.
PANCREATOLOGY (2004)
Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation
S Marktel et al.
BLOOD (2003)
Retroviral transduction of human peripheral blood lymphocytes with bcl-xL promotes in vitro lymphocyte survival in pro-apoptotic conditions
D Eaton et al.
GENE THERAPY (2002)
Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors
A Krishnan et al.
BLOOD (2000)
Share Paper
